Innovations In Drug Delivery

Insights from Patient Flows and Patient Journeys are cornerstones to the success of any pharma/medtech product. If the process of insight generation is well done, you will discover more impactful growth

There are approximately 7,000 distinct rare diseases affecting 350 million people worldwide, approximately 80 percent of which are caused by faulty genes. Scientific advances such as the CRISPR/Cas9 genome-engineering system have simplified the pharmaceutical and biotech industry’s ability to develop gene therapies, especially for single gene mutation disorders. The US Food and Drug Administration (FDA) has more than 700 active Investigational New Drug Applications (INDs) for gene and cell therapies and in 2017, the FDA approved two cell-based gene therapies and it is anticipated that gene therapy will become a mainstay treatment for many rare diseases.

In order to ensure the safety of patients, the toxicological risk assessment needs to thoroughly evaluate all potential risks which may be caused by any component present in a pharmaceutical drug product.

Learn more on burn injury, prevention and the immediate care needed for patients with burn injuries. In the United States, approximately 486,000 people seek medical treatment for burns each year. Many people may not recognize their risk of burn injury. This material will review burn injuries, including types of burns and immediate care for burns and explore the effect of burn injuries on the pulmonary, cardiac, and renal systems. It will cover the classification system used for burn injuries describe the local and systemic effects of a major burn injury, discuss the potential fluid and electrolyte alterations of the emergent/resuscitative and acute phases of burn management, describe care of the patient with burn injuries, and identify the appropriate patient referral to a burn center.